Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study
2023 · Journal of Hematology & Oncology · 18 citations
https://doi.org/10.1186/s13045-023-01448-y